The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17200%2F25%3AA2603BGS" target="_blank" >RIV/61988987:17200/25:A2603BGS - isvavai.cz</a>

Výsledek na webu

<a href="https://www.mdpi.com/2813-1851/4/3/34" target="_blank" >https://www.mdpi.com/2813-1851/4/3/34</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/psychoactives4030034" target="_blank" >10.3390/psychoactives4030034</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting

Popis výsledku v původním jazyce

Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves the way for regulated therapeutic applications of psilocybin within clinical settings, while simultaneously prompting a timely discussion on the potential uses of psychedelics beyond strictly medical contexts. This commentary first outlines the legal status of psilocybin for therapeutic use in Czechia and situates this reform within broader international policy trends. Drawing on the publication How to Regulate Psychedelics and qualitative findings from a ketamine-assisted therapy program conducted as part of the Czech Destigmatizing the Therapeutic Use of Psychedelics in Psychiatry project, it then examines the regulation of non-clinical psychedelic use, while also highlighting the persistent legal ambiguity surrounding the Czech offence of “spreading toxicomania.” The commentary advocates for a rational, evidence-based regulatory approach, arguing that while the medicalization of psilocybin constitutes a significant legal milestone, the framework will remain incomplete without clear pathways for non-clinical use to ensure safety and legal clarity.

Název v anglickém jazyce

The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting

Popis výsledku anglicky

Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves the way for regulated therapeutic applications of psilocybin within clinical settings, while simultaneously prompting a timely discussion on the potential uses of psychedelics beyond strictly medical contexts. This commentary first outlines the legal status of psilocybin for therapeutic use in Czechia and situates this reform within broader international policy trends. Drawing on the publication How to Regulate Psychedelics and qualitative findings from a ketamine-assisted therapy program conducted as part of the Czech Destigmatizing the Therapeutic Use of Psychedelics in Psychiatry project, it then examines the regulation of non-clinical psychedelic use, while also highlighting the persistent legal ambiguity surrounding the Czech offence of “spreading toxicomania.” The commentary advocates for a rational, evidence-based regulatory approach, arguing that while the medicalization of psilocybin constitutes a significant legal milestone, the framework will remain incomplete without clear pathways for non-clinical use to ensure safety and legal clarity.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

50500 - Law

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Psychoactives

ISSN

2813-1851

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

15

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—